Breast Cancer Clinical Trial
Official title:
Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can
predict the efficacy and adverse events of apatinib in patients with malignancies.
Integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated
obviously in various types of tumor cells and activated endothelial cells. The
arginine-glycine-aspartic acid (RGD) tripeptide sequence can bind to integrin αvβ3 with high
affinity and specificity. The 18F-ALF-NOTA-PRGD2 will highly combine with αvβ3, and thus will
monitor the antiangiogenic status.In the current study, investigators propose to evaluate the
feasibility of 18F-RGD PET/CT in monitoring efficacy and adverse events of apatinib in
malignancies.
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 positron
emission tomography/computed tomography (18F-RGD PET/CT) scan can predict the efficacy and
adverse events of apatinib in patients with malignancies.
Angiogenesis, the formation of new blood vessels, is the process of generating
neovascularization from preexisting vessels. It can promote tumor growth and metastasis by
providing nutrients and oxygen. Integrin αvβ3 has been shown to play an important role in
angiogenesis and up-regulated obviously in various types of tumor cells and activated
endothelial cells. Since the arginine-glycine-aspartic acid (RGD) tripeptide sequence can
bind to integrin αvβ3 with high affinity and specificity, RGD PET/CT may be helpful to
evaluate the biological and metabolic activity status during angiogenesis. However,
18F-ALF-NOTA-PRGD2 PET/CT as response biomarker for antiangiogenic therapy has not been fully
proved and is still without universal understanding according to current publications.
Apatinib (YN968D1) is the first orally antiangiogenic drug targeting VEGFR-2 tyrosine
kinase.In the current study, investigators propose to evaluate the feasibility of 18F-RGD
PET/CT in monitoring efficacy and adverse events of apatinib in malignancies. Patients
confirmed malignancies histopathologically will be prospectively enrolled in the study. All
patients provided written informed consent prior to enrollment. Patients will receive
apatinib therapy, and undergo 18F-RGD PET/CT scans berore and after first cycle of therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |